Long-term efficacy and safety of dupilumab with concomitant topical corticosteroids in Japanese pediatric patients with moderate-to-severe atopic dermatitis: Results from a phase 3 open-label extension study
This analysis supports the long-term efficacy and safety of dupilumab in Japanese patients aged ≥6 months to <18 years with moderate-to-severe atopic dermatitis.
Authors
- Kenji Yahata
- Ariane Dubost-Brama
- Elizabeth Laws
- Yoko Kataoka (ORCID: https://orcid.org/0000-0001-6268-6587)
- Jennifer Maloney
- Kazuhiko Arima (ORCID: https://orcid.org/0000-0002-0607-8787)
- Akio Tanaka (ORCID: https://orcid.org/0000-0002-5354-7064)
- Motohiro Ebisawa (ORCID: https://orcid.org/0000-0003-4117-558X)
- Mizuho Nagao (ORCID: https://orcid.org/0000-0003-3557-8761)
- Ashish Bansal (ORCID: https://orcid.org/0000-0002-7371-6486)
- Hisakatsu Nawata
- Xin Lu (ORCID: https://orcid.org/0000-0001-8304-5906)
- Daisuke Watanabe (ORCID: https://orcid.org/0000-0002-3658-5704)
Institutions
- Hiroshima University (JP)
- Regeneron (United States) (US)
- Sanofi (France) (FR)
- Osaka Prefectural Medical Center (JP)
- Sanofi (United States) (US)
- National Sagamihara Hospital (JP)
- Sanofi (Japan) (JP)
- National Mie Hospital (JP)
Publication Details
- Journal
- Allergology International
- Published
- 2025-10-16
- DOI
- https://doi.org/10.1016/j.alit.2025.09.002
- Primary Topic
- Dermatology and Skin Diseases
- Type
- article
- Field-Weighted Citation Impact
- 0.00